Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Clinical trials
373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02315612 | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | completed | Phase 1 | 134 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04088890 | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | completed | Phase 1 | 52 | Matthew FrankOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05350787 | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL | completed | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06027957 | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia | completed | Phase 1 | 18 | Vinmec Research Institute of Stem Cell and Gene TechnologyOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT03448393 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | completed | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02975687 | CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | completed | Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03472573 | Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03751709 | Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | completed | Phase 1 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04557436 | TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)(PBLTT52CAR19) | completed | Phase 1 | 9 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT03991884 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 24 | University of WashingtonOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT01029366 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | completed | Phase 1 | 26 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01925131 | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 50 | SWOG Cancer Research NetworkNETWORK | 1 | May 3, 2023 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | completed | Phase 1 | 120 | Xencor, Inc.INDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02808442 | Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia(PALL) | completed | Phase 1 | 13 | Institut de Recherches Internationales ServierOTHER | 4 | Oct 8, 2021 | clinicaltrials |
| NCT02746952 | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia(CALM) | completed | Phase 1 | 25 | Institut de Recherches Internationales ServierOTHER | 4 | Oct 1, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT00866307 | Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) | completed | Phase 1 | 104 | Children's Oncology GroupNETWORK | 3 | Apr 27, 2021 | clinicaltrials |
| NCT03289455 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)(AMELIA) | completed | Phase 1 / Phase 2 | 23 | Autolus LimitedINDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01786135 | A Safety Study of SGN-CD19A for B-Cell Lymphoma | completed | Phase 1 | 64 | Seagen Inc.INDUSTRY | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01786096 | A Safety Study of SGN-CD19A for Leukemia and Lymphoma | completed | Phase 1 | 92 | Seagen Inc.INDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 28, 2026source: clinicaltrials